This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cuschieri, K. Articles by Wentzensen, N. Search for Related Content PubMed PubMed Citation Articles by Cuschieri, K. Articles by Wentzensen, N. Related Collections Epidemiology and Prevention Epidemiology and Prevention: Screening, Behavior, and Survivorship

Human Papillomavirus mRNA and p16 Detection as Biomarkers for the Improved Diagnosis of Cervical Neoplasia

¹ Specialist Virology Centre, Royal Infirmary of Edinburgh, United Kingdom and ² Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland

Requests for reprints: Kate Cuschieri, Specialist Virology Centre, Royal Infirmary of Edinburgh, UK EH16 4SA. Phone: 00-44-131-242-6039; Fax: 00-44-131-242-6008. E-mail: Kate.Cuschieri{at}luht.scot.nhs.uk

Human papillomavirus (HPV) infection of the genital tract is very common and normally follows a benign clinical course; however, in an unfortunate minority of infected individuals, it can cause disease that sometimes leads to cancer. It is accepted that HPV DNA testing has a role in the management of cervical disease both in a prevaccination and postvaccination era; however, to improve the specificity of this approach, there is a requirement to develop and validate tools/assays that can identify women at risk for progressive disease. There is evidence to suggest that detection of viral gene expression both directly and indirectly may constitute a more specific approach for delineating clinically significant infection compared with HPV DNA–based assays. HPV oncogene expression and evidence of its deregulation can be monitored through direct detection of viral mRNA transcripts or through detection of the cellular protein p16. For both approaches, commercial assays have been introduced and numerous studies have been conducted. The present article describes the scientific theory underpinning these approaches, their amenability to routine-diagnostic specimens/settings, and the clinical data that has been garnered through their application thus far. Currently, there is promising data indicating that HPV mRNA and p16 might play an important role in future cervical cancer screening scenarios. Still, large randomized studies are necessary to confirm the preliminary data.

Methods: PubMed and OVID were interrogated with search terms "HPV RNA;" "HPV mRNA;" "HPV transcript—detection, testing, and methods;" "p16" AND "cervical cancer;" "p16" AND "CIN;" "p16" AND "histology"; "p16" AND "cytology;" "p16;" and "screening." (Cancer Epidemiol Biomarkers Prev 2008;17(10):2536–45)

This article has been cited by other articles:

				P. Cattani, A. Siddu, S. D'Onghia, S. Marchetti, R. Santangelo, V. G. Vellone, G. F. Zannoni, and G. Fadda RNA (E6 and E7) Assays versus DNA (E6 and E7) Assays for Risk Evaluation for Women Infected with Human Papillomavirus J. Clin. Microbiol., July 1, 2009; 47(7): 2136 - 2141. [Abstract] [Full Text] [PDF]